Drugs / RFT5-dgA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00667017 | Nov 2008 → Feb 2010 | lymphoma | University of Texas Southwestern Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00314093 | Apr 2006 → Nov 2008 | metastatic melanoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RFT5-dgA | “RFT5-dgA is a recombinant immunotoxin that selectively targets CD25 expressing cells in vivo.” NCT00314093 ↗ |
| Known as | IMTOX25 | “RFT5-dgA immunotoxin (also called anti-CD25 immunotoxin IMTOX25)” NCT00667017 ↗ |
| Action | Deplete | “RFT-5-dgA is an immunotoxin (substance that kills specific cells in the immune system) that kills CD25+ cells.” NCT00314093 ↗ |
| Modality | Protein / enzyme biologic | “RFT5-dgA is a recombinant immunotoxin that selectively targets CD25 expressing cells in vivo.” NCT00314093 ↗ |
| Route | Intravenous | “RFT5-dgA intravenously” NCT00314093 ↗ |
| Target | IL2RA | “the IL-2Ra-specific murine IgG1 antibody RFT5 linked to deglycosylated ricin A chain” NCT00314093 ↗ |